Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.

@article{Winter2007AssessmentOT,
  title={Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.},
  author={Jack W Winter and Dairena Gaffney and David Shapiro and Richard J. Spooner and Anthony Marin Marinaki and Jeremy David Sanderson and Peter R. Mills},
  journal={Alimentary pharmacology & therapeutics},
  year={2007},
  volume={25 9},
  pages={1069-77}
}
BACKGROUND Myelosuppression occurs in 2-7% of inflammatory bowel disease (IBD) patients treated with azathioprine, and can be associated with reduced activity of thiopurine methyltransferase (TPMT) in some patients. It has been proposed that pretreatment assessment of TPMT status reduces the incidence of toxicity and is cost-effective. AIMS To determine if screening for TPMT status predicts side-effects to azathioprine in patients with IBD and to ascertain whether screening by TPMT enzyme… CONTINUE READING
34 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…